# Investment firm fails to develop scorpion antivenom using AI model Claude

Published: 2026-10-22 · Updated: 2026-10-22 · Category: Research

Source page: https://www.sipply.dev/story/investment-firm-fails-to-develop-scorpion-antivenom-using-ai-a84567a7 · 中文: https://www.sipply.dev/zh/story/investment-firm-fails-to-develop-scorpion-antivenom-using-ai-a84567a7

## Summary

An investment research firm recently attempted to leverage an unreleased version of the AI model Claude to create a new scorpion antivenom. Although the AI generated some innovative ideas during the process, the effort ultimately did not yield a viable drug. This case underscores the current limitations of AI technology in the complex field of drug development, where human expertise and extensive testing remain crucial components.

## Key takeaways

- AI can generate creative ideas but may not be reliable for drug development.
- The attempt to use Claude for antivenom highlights the challenges in translating AI concepts into practical solutions.
- Human expertise is still essential in the drug development process, despite advancements in AI.

## Why it matters

This incident illustrates the gap between AI capabilities and real-world applications in critical fields like medicine, emphasizing the need for cautious optimism regarding AI's role in drug development.

- **Product managers:** Product managers should recognize that while AI can assist in brainstorming and idea generation, it cannot replace the rigorous processes required for successful product development in pharmaceuticals.
- **Developers:** Developers should understand the limitations of current AI models in complex problem-solving scenarios, particularly in specialized fields like drug development, where human insight is irreplaceable.
- **Students and job seekers:** Students and job-seekers should be aware that while AI is a powerful tool, it is not a panacea; understanding the interplay between AI and human expertise is crucial for future careers in tech and science.

## Sources

- [Claude did not invent scorpion antivenom](https://www.theverge.com/ai-artificial-intelligence/1016443/anthropic-claude-citrini-vibecoding-scorpion-antivenom) (The Verge AI, 2026-10-22)

## 中文

### 投资公司未能利用AI模型Claude开发蝎子抗毒素

一家投资研究公司最近尝试利用未发布的AI模型Claude创建新的蝎子抗毒素。尽管在过程中AI生成了一些创新想法，但最终未能产生可行的药物。此案例凸显了AI技术在药物开发这一复杂领域的当前局限性，人类专业知识和广泛测试仍然是关键组成部分。

**要点：**

- AI可以生成创意，但在药物开发中可能不可靠。
- 使用Claude进行抗毒素开发的尝试突显了将AI概念转化为实际解决方案的挑战。
- 尽管AI有所进步，人类专业知识在药物开发过程中仍然至关重要。

**为什么重要：** 这一事件展示了AI能力与医学等关键领域实际应用之间的差距，强调了对AI在药物开发中角色的谨慎乐观的必要性。

---
Sipply: Sip AI News Simply. https://www.sipply.dev